Is Egrifta (Tesamorelin) Legal in Wisconsin? How to Access It Legally
HealthRX.com
Tesamorelin is FDA-approved, but only as a prescription
Key numbers
- 1.4 mgEgrifta SV labeled once-daily dose, the 1.4 mg (0.35 mL) injectionSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 1.28 mgEgrifta WR labeled once-daily dose, which is not substitutable with SVSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 5%Tesamorelin patients whose HbA1c reached 6.5% or higher by week 26 (placebo 1%)Source: dailymed.nlm.nih.gov, as cited Nov 7, 2026
See the public record for Tesamorelin
At a glance
- FDA status / Approved prescription drug, BLA 022505, first approved November 10, 2010 [1]
- Approved use / Excess abdominal fat in HIV-infected adults with lipodystrophy [2][3]
- Current labels / Egrifta SV (2 mg vial) and Egrifta WR (11.6 mg vial), both dated July 29, 2026 [2][3]
- Daily dose / SV 1.4 mg; WR 1.28 mg; the two are not substitutable [2][3]
- Compounding / Not on FDA's category 2 safety-risk list; not among the six peptides in the October 2026 HHS draft policy [4][5][6]
- Sport / Prohibited at all times by WADA, section S2.2.4 [7][8]
What the FDA approval covers
Egrifta (tesamorelin acetate) was first approved on November 10, 2010, under application BLA 022505 [1]. The current labels are Egrifta SV, a 2 mg vial, and Egrifta WR, an 11.6 mg vial, both dated July 29, 2026 and both injected subcutaneously once daily [2][3].
The approved indication is narrow: reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy [2][3]. The label states that long-term cardiovascular safety has not been established, that the risk and benefit of continuing should be weighed in patients who have not lost visceral adipose tissue, and that the drug is not indicated for weight loss management because its effect on weight is neutral [2]. Tesamorelin is a growth hormone-releasing factor analog, not growth hormone itself [2].
How it is dispensed
The FDA approval record lists the Egrifta products with prescription marketing status [1].
Questions worth asking
What FDA has said about compounding
Tesamorelin is not on FDA's list of bulk drug substances that may present significant safety risks when compounded, a page dated April 22, 2026 [4], and it appears in no category of FDA's list for state-licensed pharmacies and physicians (updated May 14, 2026) or its list for outsourcing facilities (updated March 21, 2025) [9][10], so FDA has made no category-based statement about compounding it.
The October 2026 HHS draft enforcement-discretion policy for compounded peptides names six substances — BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500 — and tesamorelin is not one of them [5][6]. Absence from those lists is not an approval: compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they are marketed [5][6].
What the label says to watch for
Contraindications are pregnancy, active malignancy, disruption of the hypothalamic-pituitary axis (hypophysectomy, hypopituitarism, pituitary tumor or surgery, head irradiation or head trauma), and known hypersensitivity to tesamorelin or its excipients [2][3].
The label directs prescribers to monitor IGF-1 and consider discontinuing if levels stay high, for example above 3 SDS. Among patients treated 26 weeks, 47% had IGF-1 above 2 SDS and 36% above 3 SDS [2]. HbA1c of 6.5% or higher developed in 5% on tesamorelin versus 1% on placebo by week 26, a hazard ratio of about 3.3 (95% CI 1.4 to 9.6) [2]. Hypersensitivity reactions occurred in 4%, and injection-site reactions in 25% versus 14% on placebo over the first 26 weeks [2].
Doses and the sports rule
The Egrifta SV label specifies a 1.4 mg (0.35 mL) once-daily dose, says to reconstitute only with the provided Sterile Water for Injection, and directs that the reconstituted dose be administered immediately [2]. The Egrifta WR label specifies 1.28 mg (0.16 mL) once daily; it states that one reconstituted vial supplies seven daily doses and that the remainder is discarded seven days after mixing [3]. Both labels direct injection into the abdomen with site rotation and state that the two formulations are not substitutable [2][3].
WADA's Prohibited List names tesamorelin in section S2.2.4, the growth hormone releasing factors class covering GHRH and its analogues; it is prohibited at all times, in and out of competition, on both the 2026 and 2027 Lists [7][8].
Frequently asked questions
Is tesamorelin FDA-approved in the United States?
Is compounded tesamorelin FDA-approved?
What dose does the label give?
Can athletes use tesamorelin?
Reader questions
What people actually ask
Short answers drawn from the sources this article cites.
Can I get a prescription for tesamorelin online?
Whether a tesamorelin prescription can be obtained online is not established. Wisconsin-specific prescribing, telehealth and pharmacy rules are not addressed. The Egrifta products carry prescription marketing status, and compounded versions are not FDA-approved.
How to obtain Tesamorelin?
Tesamorelin is sold as a prescription drug. Egrifta was first approved on November 10, 2010 under application BLA 022505, and the FDA approval record lists the Egrifta products with prescription marketing status. Specific sources or steps for obtaining it are not described.
References
Show all 10 referencesHide references
- Drugs@FDA: FDA-Approved Drugs.
- U.S. National Library of Medicine, DailyMed. Egrifta SV (tesamorelin) for injection, 2 mg vial prescribing information. Egrifta SV (tesamorelin) for injection, 2 mg vial label
- U.S. National Library of Medicine, DailyMed. Egrifta WR (tesamorelin) for injection, 11.6 mg vial prescribing information. Egrifta WR (tesamorelin) for injection, 11.6 mg vial label
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- Official web page.
- Official web page.
- World Anti-Doping Agency.
- World Anti-Doping Agency.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.